| 肝细胞癌的免疫治疗研究进展 |
| |
| 引用本文： | 唐雨豪,王骏成,朱应钦,陈锦滨,张耀军,周仲国,陈敏山,徐立.肝细胞癌的免疫治疗研究进展[J].中国肿瘤临床,2019,46(9):441-446. |
| |
| 作者姓名： | 唐雨豪 王骏成 朱应钦 陈锦滨 张耀军 周仲国 陈敏山 徐立 |
| |
| 作者单位： | 中山大学肿瘤防治中心肝胆胰科，华南肿瘤学国家重点实验室，肿瘤医学协同创新中心（广州市510060） |
| |
| 基金项目： | 国家自然科学基金项目81772589国家科技重大专项项目2018ZX10302205国家科技重大专项项目2018ZX10723204 |
| |
| 摘 要： | 肝细胞肝癌(hepatocellular carcinoma,HCC)约占原发肝癌的75%~85%,是全球发病率较高的恶性肿瘤之一,免疫治疗目前被认为是较有前景的防治肝癌术后复发及病情进展的治疗手段。肝癌免疫治疗方案主要分为主动和被动免疫治疗,包括肿瘤疫苗、免疫检查点抑制剂和过继性免疫细胞输注治疗等。本文就近年肝癌免疫治疗的现状和研究进展进行概述。
|
| 关 键 词： | 肝细胞癌 免疫治疗 免疫检查点抑制剂 嵌合抗原受体T细胞 |
| 收稿时间： | 2019-01-31 |
The progress of immunotherapy for hepatocellular carcinoma |
| |
| Yuhao Tang,Juncheng Wang,Yingqin Zhu,Jinbin Chen,Yaojun Zhang,Zhongguo Zhou,Minshan Chen,Li Xu.The progress of immunotherapy for hepatocellular carcinoma[J].Chinese Journal of Clinical Oncology,2019,46(9):441-446. |
| |
| Authors: | Yuhao Tang Juncheng Wang Yingqin Zhu Jinbin Chen Yaojun Zhang Zhongguo Zhou Minshan Chen Li Xu |
| |
| Institution: | Ddepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China |
| |
| Abstract: | Hepatocellular carcinoma (HCC) accounts for approximately 75%-85% of primary liver cancer cases and is one of the most frequently diagnosed malignancies worldwide. Immunotherapy is currently considered to be the most promising treatment to prevent the progression and postoperative recurrence of HCC. At present, the treatment strategies of immunotherapy for HCC are classified as active immunotherapy and passive immunotherapy, including tumor vaccine therapy, immune checkpoint inhibitors, and adoptive cell therapy. Here we review the current clinical progression and discuss the future perspective on immune therapy for HCC. |
| |
| Keywords: | hepatocellular carcinoma (HCC) immunotherapy immune checkpoint inhibitors chimeric antigen receptor T cell |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
| 点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
